Please login to the form below

Not currently logged in
Email:
Password:

Palovarotene

This page shows the latest Palovarotene news and features for those working in and with pharma, biotech and healthcare.

Revenue growth at Ipsen numbs pain of palovarotene calamity

Revenue growth at Ipsen numbs pain of palovarotene calamity

It hopes to “define next steps for the clinical programme to bring palovarotene to patients as quickly as possible”, according to its annual results statement. ... In the near-term, Ipsen’s late-stage R&D beyond palovarotene is focused mainly on

Latest news

  • Ipsen buys rare disease group Clementia in $1.3bn deal Ipsen buys rare disease group Clementia in $1.3bn deal

    Ipsen could enter a potentially lucrative market with palovarotene for both FOP and MO, for which there are no current treatments approved for these types of diseases. ... possible. “We anticipate a smooth transition of our operations into the Ipsen

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...